| Prostate Cancer |
1 |
1 |
| Breast Cancer |
0 |
0.8 |
| Ovarian Cancer |
0 |
0.9 |
| BRCA |
0 |
0.99 |
| Cancer |
0 |
0.33 |
| Biologic Therapy |
0 |
0.29 |
| Prostate |
0 |
0.29 |
| Genomic Medicine |
0 |
0.25 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.25 |
| Prostate Specific Antigen |
0 |
0.22 |
| Fatigue |
0 |
0.21 |
| Chemotherapy |
0 |
0.17 |
| Clinical Research |
0 |
0.17 |
| Grant |
0 |
0.17 |
| Healthcare and Medical Technology |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Somatic |
0 |
0.17 |
| Taxane |
0 |
0.17 |
| Myelodysplastic Syndrome |
0 |
0.14 |
| Neutropenia |
0 |
0.09 |
| Anemia |
0 |
0.08 |
| Hemoglobin |
0 |
0.08 |
| Neutrophils |
0 |
0.08 |
| Acute Leukemia |
0 |
0.06 |
| Acute Myeloblastic Leukemia |
0 |
0.06 |
| Antigens |
0 |
0.04 |
| Arizona |
0 |
0.04 |
| Diarrhea |
0 |
0.04 |
| Leukemia |
0 |
0.04 |
| Nausea |
0 |
0.04 |
| Neuropathy |
0 |
0.04 |
| New York |
0 |
0.04 |
| Spain |
0 |
0.04 |